查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1403523

綜合代謝組測試市場至2030年的預測：按測試類型、疾病、最終用戶和地區進行的全球分析

Comprehensive Metabolic Panel Testing Market Forecasts to 2030 - Global Analysis By Test Type, Disease, End User and by Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的資料，2023年全球綜合代謝組測試市場規模為 113.2 億美元，預計在預測期內將以 11.1%的年複合成長率成長，並在2030年達到 236.5 億美元。

稱為綜合代謝組（CMP）的診斷性血液檢查可對人的代謝健康狀況進行全面評估。它評估與血糖、電解質平衡和器官功能相關的許多標記。 CMP 中通常包括血糖、電解質、肝臟、腎臟和蛋白質數值的測試。此外，該面板可以提供有關肝臟和腎臟等重要器官整體健康狀況的深入資訊，幫助識別和追蹤糖尿病、肝病和腎功能障礙等疾病。

根據國際糖尿病聯盟（IDF）的資料，全球有超過 5.4 億人患有糖尿病，到2045年，這一數字預計將增加到 7.8 億以上。

代謝性疾病發生頻率增加

推動綜合代謝組（CMP）檢測市場的主要因素之一是糖尿病、肥胖和非酒精性脂肪肝等代謝疾病的全球盛行率不斷上升。此外，鑑於與這些疾病相關的生活方式因素和用餐模式越來越普遍，定期代謝分析對於促進早期發現、介入和有效的疾病管理非常重要。

缺乏教育和意識

儘管人們越來越關注預防性醫療保健，但對於完整代謝組測試的重要性仍然存在很大的認知差距。醫療保健專業人員和公眾對這些測試提供的全面資料及其在疾病早期檢測中的重要性缺乏認知，阻礙了它們的使用。此外，為了克服這項限制，需要針對公眾和醫療保健專業人員進行有針對性的教育宣傳活動，以促進知識和積極參與代謝健康監測。

標靶治療與個人化醫療

隨著人們越來越重視個人化醫療，市場蘊藏著巨大的機會。隨著分子診斷和基因分析的不斷進步，將代謝組資料與個人遺傳資訊結合可以提高治療計劃的準確性。此外，開發適合每位患者獨特代謝特徵的標靶治療將成為可能，這有望提高治療效果並減少副作用。

價格壓力與競爭環境

CMP 測試市場面臨巨大的威脅，不僅來自價格壓力，還來自產業。由於激烈的競爭，診斷公司之間的價格競爭可能會危及綜合代謝組檢測服務的長期生存能力。此外，測試機構必須利用成本降低策略、附加價值服務和策略差異化，才能在這個競爭激烈的市場中生存，同時又不犧牲客戶滿意度。

COVID-19 的影響：

COVID-19 爆發對市場產生了多種影響。常規診斷檢測（包括 CMP 檢測）出現暫時下降，這最初是由於醫療服務中斷、供應鏈問題以及大流行管理的醫療優先事項變化所造成的。隨著醫療保健部門適應新常態，徹底的代謝評估對於確定 COVID-19 對患者（尤其是患有代謝併發症的患者）的影響的重要性越來越受到人們的認知。此外，POC 測試、遠端醫療和數位健康解決方案都因疫情而普及，改變了 CMP 測試市場的動態。

預計糖尿病領域在預測期內將是最大的領域。

糖尿病預計將佔據最大的市場佔有率，因為它是一種高度流行的慢性疾病。糖尿病是一種代謝性疾病，影響全世界數百萬人，其特徵是血糖值升高。此外，糖尿病管理市場提供廣泛的產品和服務，包括處方藥、血糖監測儀、胰島素治療和生活方式改變。由於久坐的生活方式和不良飲食等因素，糖尿病的盛行率不斷增加，人們在疾病管理的研發和創新方法方面進行了大量投資。

預計護理中心細分市場在預測期內年複合成長率最高。

市場年複合成長率最高的是即時護理中心領域。由於其易用性、速度以及簡化醫療服務的能力，現場護理測試變得越來越受歡迎。現場護理測試的特點是在患者手邊或附近位置進行快速診斷和即時結果。這些設施提供廣泛的診斷服務，並且可以在幾分鐘內提供結果。這些服務包括血液檢查、尿液檢查和其他重要的評估。此外，對分散醫療服務、改善患者就診和縮短診斷週轉時間的日益關注也推動了護理中心的擴張。

佔比最大的地區：

CMP測試市場預計將在北美地區佔據最大佔有率。該地區大量的慢性代謝病患者、發達的醫療基礎設施以及高度的預防保健意識都構成了該地區的優勢。此外，技術開拓、行業巨頭的存在、有利的償付做法等推動北美 CMP 測試市場的擴張。

年複合成長率最高的地區：

綜合代謝組（CMP）測試市場預計將成為亞太地區最高的年複合成長率。許多因素推動該地區的成長，包括人口的快速成長、醫療保健意識的提高以及代謝紊亂盛行率的增加。醫療基礎設施的改善和尖端診斷技術的引進也推動了亞太地區對全面代謝組測試的需求迅速成長。此外，由於與文明病不斷上升以及對早期檢測和管理的日益重視，預計該地區的市場將穩定成長。

免費客製化服務

訂閱此報告的客戶可以存取以下免費自訂選項之一：

  • 公司簡介
    • 其他市場參與者的綜合分析（最多3家公司）
    • 主要企業SWOT分析（最多3家公司）
  • 區域細分
    • 根據客戶興趣對主要國家的市場估計、預測和年複合成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章 執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 調查來源
    • 主要調查來源
    • 二次調查來源
    • 先決條件

第3章 市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 最終用戶分析
  • 新興市場
  • 新型冠狀病毒感染疾病（COVID-19）的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章 全球綜合代謝組測試市場：依測試類型

  • 葡萄糖
  • 鈣
  • 電解質
    • 鈉
    • 鉀
    • 其他電解質
  • 腎功能檢查
    • 血中尿素氮（BUN）
    • 肌酸酐
  • 肝功能檢查
    • 白蛋白
    • 膽紅素
    • 鹼性磷酸酶
    • 天門冬胺酸胺基轉移酶（AST）
    • 丙氨酸胺基轉移酶（ALT）
  • 蛋白質
  • 其他測試類型

第6章 全球綜合代謝組測試市場：依疾病分類

  • 糖尿病
  • 腎臟疾病
  • 肝病
  • 其他疾病

第7章 全球綜合代謝組測試市場：依最終用戶分類

  • 照護端中心
  • 診斷實驗室
  • 醫院
  • 其他最終用戶

第8章 全球綜合代謝組測試市場：依地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲

第9章 主要進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第10章 公司簡介

  • Charles River Laboratories Inc.
  • Genoptix Inc.
  • Baptist Health Medical Group
  • ARUP Laboratories
  • Scion Lab Services LLC
  • NeoGenomics Laboratories, Inc.
  • Abbott Laboratories
  • Unipath
  • Siemens HealthCare GmbH
  • Nova Medical
  • CENTOGENE NV
  • Quest Diagnostics Incorporated
  • Cleveland HeartLab, Inc.
  • Sonic HealthCare
  • TCG Corp.
  • SYNLAB International GmbH
Product Code: SMRC24748

According to Stratistics MRC, the Global Comprehensive Metabolic Panel Testing Market is accounted for $11.32 billion in 2023 and is expected to reach $23.65 billion by 2030 growing at a CAGR of 11.1% during the forecast period. A diagnostic blood test called a Comprehensive Metabolic Panel (CMP) offers a thorough assessment of a person's metabolic health. It assesses a number of markers linked to blood sugar, electrolyte balance, and organ function. Tests for glucose, electrolytes, and liver, kidney, and protein levels in the blood are commonly included in a CMP. Moreover, this panel helps identify and track diseases like diabetes, liver disease, and kidney dysfunction by providing insightful information about the general health of important organs like the liver and kidneys.

According to International Diabetes Federation (IDF), over 540 million people are suffering from diabetes worldwide, and by 2045 the numbers are expected to cross 780 million marks.

Market Dynamics:

Driver:

Increased frequency of metabolic illnesses

One major factor propelling the market for Comprehensive Metabolic Panel (CMP) testing is the rising prevalence of metabolic disorders worldwide, such as diabetes, obesity, and non-alcoholic fatty liver disease. Additionally, regular metabolic profiling is imperative to facilitate early detection, intervention, and efficient disease management, given the increasing prevalence of lifestyle factors and dietary patterns associated with these conditions.

Restraint:

Low level of education and awareness

Even with the growing focus on preventive healthcare, there is still a significant knowledge gap about the significance of full metabolic panel testing. The lack of awareness among healthcare professionals and the general public regarding the comprehensive range of data these tests offer and their significance in the early identification of illnesses impedes their use. Furthermore, in order to overcome this limitation, focused education campaigns that foster knowledge and proactive participation in metabolic health monitoring are required, aimed at both the general public and healthcare professionals.

Opportunity:

Targeted therapies and personalized medicine

There is a big chance for the market because of the growing emphasis on personalized medicine. The precision of treatment plans can be improved by combining metabolic panel data with individual genetic information as molecular diagnostics and genetic profiling continue to advance. Moreover, this makes it possible to develop targeted therapies that are suited to each patient's particular metabolic profile, enhancing treatment effectiveness and reducing side effects.

Threat:

Pricing pressure and the competitive environment

The CMP testing market is significantly threatened by the industry as well as pricing pressures. A pricing war amongst diagnostic companies could jeopardize the long-term viability of comprehensive metabolic panel testing services due to intense competition. Additionally, laboratories must use cost-cutting strategies, value-added services, and strategic differentiation to survive in this cutthroat market without sacrificing customer satisfaction.

COVID-19 Impact:

There are several ways in which the COVID-19 pandemic has affected the market. A brief drop in routine diagnostic testing, including CMP tests, was initially caused by disruptions in healthcare services, issues with the supply chain, and a change in healthcare priorities toward managing the pandemic. The significance of thorough metabolic assessments in determining the effects of COVID-19 on patients, particularly those with metabolic complications, was acknowledged more as the healthcare sector adjusted to the new normal. Furthermore, point-of-care testing, telemedicine, and digital health solutions have all seen rapid adoption as a result of the pandemic, which has changed the dynamics of the CMP testing market.

The Diabetes segment is expected to be the largest during the forecast period

Due to the fact that diabetes is a chronic condition with a high prevalence, it is expected to hold the largest share of the market. Diabetes is a metabolic disease that affects millions of people worldwide and is typified by elevated blood glucose levels. Moreover, a broad range of goods and services are available in the diabetes management market, such as prescription drugs, glucose monitors, insulin treatments, and lifestyle modifications. Significant investments have been made in research, development, and creative approaches to disease management as a result of the rising prevalence of diabetes, which is fueled by factors like sedentary lifestyles and poor dietary habits.

The Point of care Centers segment is expected to have the highest CAGR during the forecast period

The market's highest CAGR is being seen in the point-of-care centers segment. Point-of-care testing has become increasingly popular because of its ease of use, speed, and capacity to simplify the delivery of healthcare. It is typified by quick diagnostics and real-time results at or close to the patient. These facilities provide a broad range of diagnostic services, with results available in a matter of minutes. These services include blood tests, urinalysis, and other crucial assessments. Additionally, point-of-care center expansion has been driven by the growing emphasis on decentralizing healthcare services, increasing patient accessibility, and shortening diagnosis turnaround times.

Region with largest share:

The market for CMP testing is expected to have the largest share in the North American region. A large patient population with chronic metabolic conditions, a well-established healthcare infrastructure, and a high level of awareness regarding preventive healthcare are some of the factors contributing to the region's dominance. Furthermore, technology developments, the existence of major industry players, and advantageous reimbursement practices have all aided in the expansion of the CMP testing market in North America.

Region with highest CAGR:

The comprehensive metabolic panel (CMP) testing market is expected to grow at the highest CAGR in the Asia-Pacific region. A number of factors are driving the region's growth, such as a quickly growing population, growing healthcare awareness, and an increase in the prevalence of metabolic disorders. The Asia-Pacific region's burgeoning need for comprehensive metabolic panel testing is partly due to improved healthcare infrastructure and the uptake of cutting-edge diagnostic technologies. Moreover, the market in this region is expected to grow at a robust rate due to the increasing prevalence of lifestyle-related diseases and the growing emphasis on early detection and management.

Key players in the market:

Some of the key players in Comprehensive Metabolic Panel Testing market include Charles River Laboratories Inc., Genoptix Inc., Baptist Health Medical Group, ARUP Laboratories, Scion Lab Services LLC, NeoGenomics Laboratories, Inc., Abbott Laboratories, Unipath, Siemens Healthcare GmbH, Nova Medical, CENTOGENE N.V., Quest Diagnostics Incorporated, Cleveland HeartLab, Inc., Sonic Healthcare, TCG Corp. and SYNLAB International GmbH.

Key Developments:

In December 2023, Charles River Laboratories International, Inc. announced an important milestone in their strategic collaboration to manufacture CASGEVY™. CASGEVY is approved in some countries for certain eligible patients. The news follows Charles River's Memphis center of excellence passing back-to-back audits from both the U.S. Food and Drug Administration and the Health Products Regulatory Authority, on behalf of the European Medicines Agency.

In December 2023, Baptist Health Baptist Hospital launched the Inspiration Hall, powered by national leader in hospice and palliative care services, VITAS Healthcare. Located on the first floor near the hospital's imaging center waiting room, the Inspiration Hall is an immersive experience where patients, visitors and hospital team members can submit, read or watch messages of comfort and support that will inspire others in their health journey.

In December 2023, A partnership between ARUP Laboratories and Medicover has made a new companion diagnostic, and thereby a new gene therapy, more accessible to patients in the European Union. ARUP Laboratories, in close collaboration with BioMarin Pharmaceutical Inc., developed AAV5 DetectCDx™, a companion diagnostic that aids in the selection of adult patients with severe hemophilia A who are eligible for treatment with ROCTAVIAN™, a new gene therapy developed by BioMarin.

Test Types Covered:

  • Glucose
  • Calcium
  • Electrolytes
  • Kidney Function Tests
  • Liver Function Tests
  • Proteins
  • Other Test Types

Diseases Covered:

  • Diabetes
  • Kidney Disease
  • Liver Disease
  • Other Diseases

End Users Covered:

  • Point of Care Centers
  • Diagnostic Laboratories
  • Hospitals
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Comprehensive Metabolic Panel Testing Market, By Test Type

  • 5.1 Introduction
  • 5.2 Glucose
  • 5.3 Calcium
  • 5.4 Electrolytes
    • 5.4.1 Sodium
    • 5.4.2 Potassium
    • 5.4.3 Other Electrolytes
  • 5.5 Kidney Function Tests
    • 5.5.1 Blood Urea Nitrogen (BUN)
    • 5.5.2 Creatinine
  • 5.6 Liver Function Tests
    • 5.6.1 Albumin
    • 5.6.2 Bilirubin
    • 5.6.3 Alkaline Phosphatase
    • 5.6.4 Aspartate Aminotransferase (AST)
    • 5.6.5 Alanine Aminotransferase (ALT)
  • 5.7 Proteins
  • 5.8 Other Test Types

6 Global Comprehensive Metabolic Panel Testing Market, By Disease

  • 6.1 Introduction
  • 6.2 Diabetes
  • 6.3 Kidney Disease
  • 6.4 Liver Disease
  • 6.5 Other Diseases

7 Global Comprehensive Metabolic Panel Testing Market, By End User

  • 7.1 Introduction
  • 7.2 Point of Care Centers
  • 7.3 Diagnostic Laboratories
  • 7.4 Hospitals
  • 7.5 Other End Users

8 Global Comprehensive Metabolic Panel Testing Market, By Geography

  • 8.1 Introduction
  • 8.2 North America
    • 8.2.1 US
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 Italy
    • 8.3.4 France
    • 8.3.5 Spain
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 Japan
    • 8.4.2 China
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 New Zealand
    • 8.4.6 South Korea
    • 8.4.7 Rest of Asia Pacific
  • 8.5 South America
    • 8.5.1 Argentina
    • 8.5.2 Brazil
    • 8.5.3 Chile
    • 8.5.4 Rest of South America
  • 8.6 Middle East & Africa
    • 8.6.1 Saudi Arabia
    • 8.6.2 UAE
    • 8.6.3 Qatar
    • 8.6.4 South Africa
    • 8.6.5 Rest of Middle East & Africa

9 Key Developments

  • 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 9.2 Acquisitions & Mergers
  • 9.3 New Product Launch
  • 9.4 Expansions
  • 9.5 Other Key Strategies

10 Company Profiling

  • 10.1 Charles River Laboratories Inc.
  • 10.2 Genoptix Inc.
  • 10.3 Baptist Health Medical Group
  • 10.4 ARUP Laboratories
  • 10.5 Scion Lab Services LLC
  • 10.6 NeoGenomics Laboratories, Inc.
  • 10.7 Abbott Laboratories
  • 10.8 Unipath
  • 10.9 Siemens HealthCare GmbH
  • 10.10 Nova Medical
  • 10.11 CENTOGENE N.V.
  • 10.12 Quest Diagnostics Incorporated
  • 10.13 Cleveland HeartLab, Inc.
  • 10.14 Sonic HealthCare
  • 10.15 TCG Corp.
  • 10.16 SYNLAB International GmbH

List of Tables

  • Table 1 Global Comprehensive Metabolic Panel Testing Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Comprehensive Metabolic Panel Testing Market Outlook, By Test Type (2021-2030) ($MN)
  • Table 3 Global Comprehensive Metabolic Panel Testing Market Outlook, By Glucose (2021-2030) ($MN)
  • Table 4 Global Comprehensive Metabolic Panel Testing Market Outlook, By Calcium (2021-2030) ($MN)
  • Table 5 Global Comprehensive Metabolic Panel Testing Market Outlook, By Electrolytes (2021-2030) ($MN)
  • Table 6 Global Comprehensive Metabolic Panel Testing Market Outlook, By Sodium (2021-2030) ($MN)
  • Table 7 Global Comprehensive Metabolic Panel Testing Market Outlook, By Potassium (2021-2030) ($MN)
  • Table 8 Global Comprehensive Metabolic Panel Testing Market Outlook, By Other Electrolytes (2021-2030) ($MN)
  • Table 9 Global Comprehensive Metabolic Panel Testing Market Outlook, By Kidney Function Tests (2021-2030) ($MN)
  • Table 10 Global Comprehensive Metabolic Panel Testing Market Outlook, By Blood Urea Nitrogen (BUN) (2021-2030) ($MN)
  • Table 11 Global Comprehensive Metabolic Panel Testing Market Outlook, By Creatinine (2021-2030) ($MN)
  • Table 12 Global Comprehensive Metabolic Panel Testing Market Outlook, By Liver Function Tests (2021-2030) ($MN)
  • Table 13 Global Comprehensive Metabolic Panel Testing Market Outlook, By Albumin (2021-2030) ($MN)
  • Table 14 Global Comprehensive Metabolic Panel Testing Market Outlook, By Bilirubin (2021-2030) ($MN)
  • Table 15 Global Comprehensive Metabolic Panel Testing Market Outlook, By Alkaline Phosphatase (2021-2030) ($MN)
  • Table 16 Global Comprehensive Metabolic Panel Testing Market Outlook, By Aspartate Aminotransferase (AST) (2021-2030) ($MN)
  • Table 17 Global Comprehensive Metabolic Panel Testing Market Outlook, By Alanine Aminotransferase (ALT) (2021-2030) ($MN)
  • Table 18 Global Comprehensive Metabolic Panel Testing Market Outlook, By Proteins (2021-2030) ($MN)
  • Table 19 Global Comprehensive Metabolic Panel Testing Market Outlook, By Other Test Types (2021-2030) ($MN)
  • Table 20 Global Comprehensive Metabolic Panel Testing Market Outlook, By Disease (2021-2030) ($MN)
  • Table 21 Global Comprehensive Metabolic Panel Testing Market Outlook, By Diabetes (2021-2030) ($MN)
  • Table 22 Global Comprehensive Metabolic Panel Testing Market Outlook, By Kidney Disease (2021-2030) ($MN)
  • Table 23 Global Comprehensive Metabolic Panel Testing Market Outlook, By Liver Disease (2021-2030) ($MN)
  • Table 24 Global Comprehensive Metabolic Panel Testing Market Outlook, By Other Diseases (2021-2030) ($MN)
  • Table 25 Global Comprehensive Metabolic Panel Testing Market Outlook, By End User (2021-2030) ($MN)
  • Table 26 Global Comprehensive Metabolic Panel Testing Market Outlook, By Point of Care Centers (2021-2030) ($MN)
  • Table 27 Global Comprehensive Metabolic Panel Testing Market Outlook, By Diagnostic Laboratories (2021-2030) ($MN)
  • Table 28 Global Comprehensive Metabolic Panel Testing Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 29 Global Comprehensive Metabolic Panel Testing Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.